News

A study found no major differences in overall cancer risk among adalimumab, secukinumab, and ustekinumab for psoriasis.

Maher discussed taladegib's potential to improve FVC, rather than slow decline, in people with idiopathic pulmonary fibrosis.

This analysis highlights the impact of dermatology consultations on HS management within acute care settings.

Investigators estimate that replacing individually prescribed school-based devices with spare adrenaline autoinjectors could improve access for students.

Late-breaking data at CHEST 2025 support the novel combination therapy, which may be submitted to the FDA in application for patients with OSA in coming months.

Kolaitis discussed interim findings from the ASCENT trial, which showed ability to increase treprostinil dosing while maintaining a safe and efficacious profile.

Castro discusses new data from CHEST 2025 showing the value of baseline blood eosinophils and FeNO in understanding potential dupilumab outcomes.

Imran Satia, MD, PhD, discusses promising phase 2A trial data showing quick and significant improvements in patients' perception of cough frequency and severity.

A recent study from Duke University spotlighted papSCAR’s substantial association with both cardiovascular mortality and arrhythmia.

SelectION, Inc. has announced positive topline findings from its phase 1b proof-of-concept study assessing si-544 in those with psoriasis vulgaris.

Adults given an initial 0.5 mg intramuscular epinephrine dose were less likely to need further intervention than those receiving 0.3 mg, a study found.

View slated expert interviews and 6 clinical GI, hepatology, and endoscopy trials to watch at ACG 2025.

JAK inhibitors have transformed the world of treatment for inflammatory disease, and views on their safety and efficacy have also transformed over the years.

The ACP Performance Measurement Committee reviewed 5 performance measures for CRC screening, ultimately only supporting 1 of them.

Sheth discusses the positive results in nAMD and PCV, highlighting faricimab’s capacity for dose extension and maintaining vision.

In a recent study, a 30 mg maintenance dose significantly increased reaction thresholds and improved immune markers in children with peanut allergy.

Despite clinical definitions suggesting patients recover from exacerbations within 2 weeks of hospital discharge, most patients in a qualitative survey believed they had not achieved recovery within 3 months.

A total of 8 acute and chronic disease factors, including hypertension, obesity, and physical inactivity, compound to increase mortality and CVD risk.

Evidence-based guidelines from emphasize personalized transfusion strategies for critically ill patients, urging clinicians to avoid routine platelet and fresh frozen plasma transfusions during common procedures.

Wood shares 3 factors that influencing our nationally poor rates of high-risk lung cancer screening.

McCormack believes simple lung function results accrued over a lifetime can optimize an individual's pulmonary care.

A new study finds that rates of peanut and other IgE-mediated food allergies declined following the 2015 and 2017 early peanut introduction guidelines.

This approval represents an alternative method for approaching this undertreated disease, shortening recovery while minimizing invasiveness.

RAPT Therapeutics and Shanghai Jeyou Pharmaceutical announced these new findings on RPT904 (JYB1904) in chronic spontaneous urticaria.

An audio recap of the top 5 stories in healthcare news from the week of 10/12-18.

The study showed that infants consuming blueberries had lower IL-13, higher IL-10, and improved allergy symptom trajectories compared with placebo.

Rybelsus marks the first oral GLP-1 for major adverse cardiovascular events in adult patients with T2D, opening a new cardiovascular treatment pathway.

Retrospective cohort data at CHEST 2025 show the similar efficacy profiles — but slightly different safety outcomes — among patients receiving either biologic.